Abstract
Methods: A novel series of isoxazole (S21-S30) derivatives were designed, synthesized and screened for their anticancer activity against estrogen receptor-positive MCF-7 and negative MDA-MB-435 breast cancer cell lines. The synthesized derivative has the ability to inhibit the growth of the human breast cancer cell line at low concentrations. In vivo anticancer activity was performed on virgin female sprague dawley rats.
Results: The result shows that compound S23 has more selectivity and marked estrogen modulator activity than the standard tamoxifen.
Keywords: Chalcone, isoxazole, breast cancer, estrogen receptor, S21-S30, tamoxifen.
Graphical Abstract
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Analytical Chemistry
Current Computer-Aided Drug Design
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Related Books
Molecular Aspects of Hepatocellular Carcinoma
Physiopathogenesis of Hematological Cancer
Molecular Oncology: Principles and Recent Advances
Dynamics of Biological Macromolecules by Neutron Scattering
Anti-Obesity Drug Discovery and Development
Multiple Myeloma - A New Era of Treatment Strategies
Stochastic Lagrangian Modeling for Large Eddy Simulation of Dispersed Turbulent Two-Phase Flows
Molecular Mechanism and Morphology in Cancer
New Developments in Medicinal Chemistry
Reviews in Pharmaceutical & Biomedical Analysis
31
11